ST. JOSEPH, Mo., May 9, 2017 /PRNewswire/ -- AgriLabs® has received a U.S. patent for ENABL® adjuvant technology and its use as a delivery system for DNA vaccines in development. The patent covers a broad range of adjuvant compositions and methods for human and animal health.
"This is a major step in commercializing our DNA vaccine platform for a number of animal species," says Steve Schram, AgriLabs president and CEO. "DNA vaccines offer tremendous promise in terms of efficacy, safety and convenience, and ENABL technology is unique in its ability to help realize that potential."
The Promise of DNA Vaccines
DNA vaccines help fight animal diseases far faster than conventional vaccines, Schram says. They don't expose treated animals to pathogens or allow those pathogens to mutate to a virulent form. The vaccines provide the ability to differentiate among infected and vaccinated animals (DIVA).
ENABL adjuvant technology provides efficient delivery of DNA-based vaccines, which results in a higher antigen absorption and immune response, says Dr. Tim Miller, chief scientific officer of AgriLabs.
"ENABL adjuvants feature a lipid/polymer matrix that allows for more efficient delivery of DNA and traditional vaccines to target cells," Miller says. "We have an expandable platform that can address issues such as reduced number of doses for DNA vaccines, which makes them economically viable options."
AgriLabs DNA vaccines are stable at room temperature or in refrigeration, providing ease of transport and storage, Miller adds.
Opportunities Across Species
AgriLabs is working to secure USDA approval for its DNA vaccine platform and developing vaccines for poultry, swine, cattle and other food animals in the U.S. The company is seeking commercial partners to license the platform for companion animals and food animals outside the U.S.
"Our DNA platform, including ENABL adjuvant technology, represents the next generation of biological innovation in animal health," Schram says. "We're pleased to be recognized with the granting of a patent for this significant step forward."
About AgriLabs: AgriLabs® is a leader in biological innovation for animal health in the United States. Through proprietary DNA platform and adjuvant technologies, AgriLabs is delivering the next generation of vaccine solutions for farm animals. These technologies – combined with other innovative products and the leading distribution network in the United States – uniquely position AgriLabs to improve animal health, nutrition and productivity. For more information, visit agrilabs.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/broad-patent-granted-for-enabl-adjuvant-technology-300454220.html